Follow Us
© 2026 Arizent. All rights reserved.
Second in a series
With high-cost claimants accounting for just 5% of the population but driving as much as half of all medical bills, precision medicine holds the key to improving treatment and reducing cost of care for a combination of chronic and complex, life-threatening conditions. The latter is largely comprised of cases that include solid tumors and hematologic malignancies, as well as neurodegenerative, autoimmune and rare diseases.
Dr. Jennifer Levin Carter is the founder and CEO of Medzown, and venture partner at Sandbox Industries.
For reprint and licensing requests for this article, click here.
With health benefit costs expected to rise 8.2% in 2027, employers are looking for ways to control spending without simply shifting more costs to workers.
As costs to treat serious conditions surge, employers must plan how to absorb budget-altering expenses ahead of time.
Providing better access to primary care providers is key to cutting down on workers' serious medical conditions and encouraging a better quality of life.
As the scope of gene therapy grows, understanding their impact and cost can help organizations decide how to cover them through their healthcare plans.
Better benefit plan design and HSAs can support employees as they struggle to afford their medical bills.
